13:35 , Mar 29, 2019 |  BC Week In Review  |  Company News

Pain Therapeutics rebrands as Cassava

Pain Therapeutics Inc. changed its name and ticker to Cassava Sciences Inc. (NASDAQ:SAVA). The rebrand reflects the company’s shift in focus to developing therapies for Alzheimer’s disease and other neurodegenerative diseases announced in August 2018...
19:00 , Feb 7, 2019 |  BC Week In Review  |  Clinical News

Pain Therapeutics chides FDA for 'shambolic' abuse-deterrent regulations

Pain Therapeutics Inc. (NASDAQ:PTIE) said FDA's regulatory procedures for gaining approval of abuse deterrent products lacks predictive pathways for development and commercialization. The company's comments follow a Jan. 31 meeting with FDA to discuss an...
23:18 , Feb 5, 2019 |  BC Extra  |  Company News

Pain Therapeutics chides FDA for 'shambolic' abuse-deterrent regulations

Pain Therapeutics Inc. (NASDAQ:PTIE) said FDA's regulatory procedures for gaining approval of abuse deterrent products lacks predictive pathways for development and commercialization. The company's comments Tuesday follow a Jan. 31 meeting with FDA to discuss...
00:04 , Oct 12, 2018 |  BC Innovations  |  Emerging Company Profile

Spinogenix’s Spine Craft

Spinogenix Inc. is developing small molecules for cognitive impairment in neurodegenerative diseases that rebuilds dendritic spines to reverse, not just halt, synaptic loss. CNS synapses that relay signals involved in memory and cognitive function are...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
06:11 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Pain shifting to AD following fourth Remoxy CRL

Pain Therapeutics Inc. (NASDAQ:PTIE) fell $1.11 (47%) to $1.25 on Aug. 6 after receiving its fourth complete response letter from FDA for pain candidate Remoxy ER oxycodone extended release (PF-00345439). The company does not plan...
18:34 , Aug 6, 2018 |  BC Extra  |  Company News

Pain shifting to AD following fourth Remoxy CRL

Pain Therapeutics Inc. (NASDAQ:PTIE) fell $1.11 (47%) to $1.25 on Monday after receiving its fourth complete response letter from FDA for pain candidate Remoxy ER oxycodone extended release (PF-00345439). The company does not plan to...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
18:20 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

FDA advisory committee votes against approval of Pain's Remoxy

At a June 26 joint meeting, FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 14-3 against approval of Remoxy ER oxycodone extended release (PF-00345439) from Pain...
19:03 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

FDA sets advisory committee date for Pain's Remoxy

Pain Therapeutics Inc. (NASDAQ:PTIE) said an FDA advisory committee will meet on June 26 to discuss an NDA for Remoxy ER oxycodone extended release (PF-00345439) to manage pain severe enough to require daily, around-the-clock, long-term...